bullish

Landos Biopharma Inc (LABP) - Tuesday, Apr 16, 2024

259 Views17 Jul 2024 05:13
Syndicated
SUMMARY
  • Biopharma company LABP targeted for takeover by AbbVie with offer of $20.42 cash per share and CVR potentially worth over $11
  • Deal valued at $137.5 million in cash and $75 million in contingent value rights, expected to close in Q2 2024
  • CVR presents opportunity for potentially lucrative payout but comes with risks associated with illiquid securities

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
chart-bar
Price Chart(Sign Up to Access)
analytics-chart
  • Loading...
x